22 May 2013
Keywords: eisai, reports, progress, dementia, drug, japan, said
Article | 02 October 1995
Eisai of Japan has said that its compound E2020 has shown "encouraging
US Phase III clinical trials results" in the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 October 1995
21 May 2013
© 2013 thepharmaletter.com